Robert Brodsky

Medicine & Life Sciences

1. Paroxysmal Hemoglobinuria 100%
2. Cyclophosphamide 64%
3. eculizumab 45%
4. Aplastic Anaemia 41%
5. Bone Marrow Transplantation 35%
6. Graft vs Host Disease 27%
7. Haploidentical Transplantation 25%
8. Transplantation 24%
9. Hemolysis 23%
10. Bone Marrow 22%
11. Transplants 20%
12. Complement Activation 18%
13. Atypical Hemolytic Uremic Syndrome 17%
14. Complement Inactivating Agents 16%
15. Tissue Donors 15%
16. ravulizumab 14%
17. Alternative Complement Pathway 14%
18. Stem Cells 12%
19. Therapeutics 12%
20. Haemolytic Anaemia 11%
21. Thrombotic Microangiopathies 11%
22. Mutation 11%
23. aerolysin 10%
24. Immunosuppressive Agents 10%
25. Homologous Transplantation 10%
26. Thrombotic Thrombocytopenic Purpura 10%
27. Hematopoietic Stem Cells 9%
28. Bone Marrow Failure Disorders 9%
29. Progression-Free Survival 8%
30. Sickle Cell Anemia 8%
31. Recurrence 8%
32. Thrombosis 7%
33. Survival 7%
34. Myelodysplastic Syndromes 6%
35. Autoimmune Haemolytic Anaemia 6%
36. Busulfan 6%
37. Acute Myeloid Leukemia 6%
38. Complement Factor D 6%
39. Hematopoiesis 6%
40. Mortality 5%
41. Confidence Intervals 5%
42. Rituximab 5%
43. Genes 5%
44. Hematopoietic Stem Cell Transplantation 5%
45. Antiphospholipid Syndrome 5%
46. Hematologic Neoplasms 5%
47. Autoimmune Diseases 5%
48. Systemic Lupus Erythematosus 5%
49. Hemoglobins 5%